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Abstract
Background: The present study was in quested to study the effects of β-sitosterol on methyl nitrosourea (MNU)
induced mammary gland carcinoma in albino wistar rats.
Methods: Animals were randomized and divided into four groups of eight animals each. Group I (sham control
1 % CMC in normal saline p.o.); Group II (toxic control, MNU 47 mg/kg, i.v); Group III (MNU 47 mg/kg, i.v + β-
sitosterol, 10 mg/kg, p.o); Group IV (MNU 47 mg/kg, i.v + β-sitosterol, 20 mg/kg, p.o). Toxicity was induced by single
i.v. injection of MNU followed by β-sitosterol supplementation therapy for 115 days at the dose mentioned above.
Results: Treatment with β-sitosterol evidenced decrease in the alveolar bud and lobule score in the whole mount
of the mammary gland. β-sitosterol exhibited diminishing effect on oxidative stress through synchronizing lipid and
enzymatic antioxidant defense. A significant decrease in the saturated and unsaturated fatty acid was evident with
the MNU treatment and β-sitosterol demonstrated a marked effect on it. Pgp 9.5 expression was dose dependently
upregulated by β-sitosterol treatment in comparison to MNU treatment. On the contrary, downregulated NF-kB
expression was perceived, when β-sitosterol was concomitantly administered with MNU.
Conclusion: β-sitosterol afforded significant protection against the deleterious effects of MNU.
Keywords: β-sitosterol, Mammary gland, P-glycoprotein, Oxidative stress, Inflammation, FAME
Background
Cancer is a one of the most life-threatening disease
worldwide. Mammary gland cancer constitutes about
10 % of the total cancer population [1]. However alter-
ation in cell membrane integrity, dysregulated apoptotic
pathway along with other inflammatory changes are
reported to play a crucial role [2, 3].
Recent findings have demonstrated that the dietary
factors including fat and other phytochemicals may offer
protection against mammary gland carcinoma, infact,
controlled dietary preclinical studies are suggestive that
the phytosterols may offer protection from a wide array
of cancers including mammary gland carcinoma [4–7].
The phytosterols are the cholesterol-like compounds ex-
clusively synthesized by plants, and it is hypothesized
that phytosterols can induce apoptosis/programmed cell
death in highly proliferating tumor cells [8–10]. Hence-
forth, β-sitosterol has been evaluated against a variety of
cancers using preclinical experimental models [11, 12].
The studies have suggested potential efficacy of β-
sitosterol particularly towards colon cancer, prostate
cancer and leukemia [13–16]. On the same line, few pre-
liminary studies have also demonstrated that β-sitosterol
can induce apoptosis by activating fatty acid synthase
(FAS) signaling in MCF-7 cells [17].
Additionally, Pgp-9.5 (ubiquitin COOH-terminal ester-
ase L1 or UCHL-1) is an ubiquitin COOH terminal
hydrolase that is widely expressed in different type of can-
cer cells [18]. Recent study demonstrated that Pgp-9.5 is
highly overexpressed at many non-neuronal tumors, in-
cluding breast, colorectal and pancreatic tumors [19].
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Considering the same, the present study was under-
taken to study the effect of β-sitosterol on Pgp expres-
sion and cellular lipids in methyl nitrosourea (MNU)
induced mammary gland carcinoma in female albino
rats. The study also extends its horizon towards elucidat-
ing the biochemical and inflammatory paradigms as




MNU was purchased from Sigma-Aldrich Co. St. Louise
Mo 63103 USA. β-sitosterol was purchased from
Cayman Chemical Company, Michigan, USA. All other
chemicals were of analytical grade and obtained from
Himedia Laboratories, Mumbai, India, else otherwise
stated in the text.
Experimental protocol
Albino wistar female rats of 100–120 g body weight
were used for the study. The rats were procured from
the central animal house facility. The animals were
housed in propylene cages under controlled conditions
(23 °C, 12 h light/ dark cycle) with free access to com-
mercial pellet diet and water. Animals were acclimatized
for two weeks before the commencement of the experi-
ment. Animals were randomized and divided into 4
groups of 8 animals each. Group I (sham control 1 %
CMC in normal saline p.o.); Group II (toxic control,
MNU 47 mg/kg, i.v); Group III (MNU 47 mg/kg, i.v + β-
sitosterol, 10 mg/kg, p.o); Group IV (MNU 47 mg/kg,
i.v + β-sitosterol, 20 mg/kg, p.o). Toxicity was induced
by single i.v. injection of MNU followed by β-sitosterol
supplementation therapy for 115 days at the dose men-
tioned above. The blood samples were collected under
chloroform anesthesia through retro-orbital plexus in
centrifugation tubes. The blood samples were incubated
at 37 °C for 1 h and centrifuged at 10,000 rpm for
15 min to collect serum. The serum samples were stored
at −20°C till further use. Animals were sacrificed on the
116th day and subjected to the following estimation.
Mammary gland whole mount
The fourth abdominal mammary glands obtained were
dissected, stretched onto a slide, placed in a fixative so-
lution and stained with a carmine aluminum solution to
prepare whole mounts [20]. Whole mounts were exam-
ined under the 4X microscope and evaluated to assess
the number of alveolar buds/terminal end buds (AB/
TEB). The whole mounts were also evaluated for ductal
elongation and differentiation. Ductal elongation was
measured, using a ruler, as the distance (in cm) from the
nipple to the end of the epithelial tree. Mammary gland
differentiation was assessed by scoring the number of
alveolar buds (ABs) type 1 and type 2. The score values
(0–5) from AB1 and AB2 were added for a final differen-
tiation score (0–10). The average rating values (0–5)
from AB1 and AB2 were added to the lobule score
values (0–5) for a final differentiation score (0–10) [20].
Biochemical estimation
The mammary gland tissues (10 % w/v) were homoge-
nized in 0.15 M KCl and centrifuged at 10,000 rpm. The
supernatants were scrutinized for biochemical parame-
ters including thiobarbituric acid reactive substances
(TBARs), superoxide dismutase (SOD), catalase and
glutathione (GSH) using the methods established in our
laboratory [21–24].
Determination of Nitric Oxide (NO) level in serum
Generation of NO in the serum samples was arbitrated
by measuring nitrite accumulation, using Griess reagent
[1 % sulphanilamide, 0.1 % N-(1-napthyl)-ethylenedi-
amine dihydrochloride in 5 % H3P04].
Equal quantity (500 μl) of serum and Griess reagent
were mixed and incubated at 37 °C for 5 min. The test
mixture was subsequently read on the UV-Visible spec-
trophotometer (Cary60, Agilent Technologies, CA95051,
US) at 540 nm [25].
Enzymatic activity of COX and LOX
A 10 % mammary gland tissue homogenate in TRIS buffer
(50 mM) was centrifuged at 5000 rpm for 5 min followed
by sonication. The tissue supernatant (10 μl) was incu-
bated for 5 min with TRIS buffer (160 μl). A 10 μl each of
TMPD reagent and arachidonic acid (AA) solution were
added and read at 630 nm using a multiplate reader
(ALERE Microplate Reader, AM-2100) at 0 and 30 s inter-
val. AA solution was prepared by mixing 50 μl of 40 mM
AA with 50 μl of 0.1 N potassium hydroxide using vortex-
ing and subsequently 900 μl of double distilled water.
TMPD stock solution was prepared by dissolving 0.3 mg
in 1 ml of distilled water and subsequent 1:10 dilution was
prepared for the assay [26, 27].
For LOX assay, 25 μl of AA solution was added to the
475 μl supernatant (as prepared for COX assay) and
incubated for 6 min. A 500 μl of ferrithiocyanate (FTC)
reagent was added and read at 480 nm using U V spec-
trophotometer (Cary 60, Agilent Technologies Inter-
national Private Limited, CA United States) after 5 min.
FTC reagent was prepared by mixing the reagent 1
(4.5 mM FeSO4 in 0.2 M HCl) and reagent 2 (3 %
NH4SCN methanolic solution) in 1:1 ratio [28].
Fatty acid methyl ester (FAME) analysis of mammary
gland tissue
Mammary gland tissue homogenate (0.5 %) was pre-
pared in the mixture of chloroform: methanol (2:1) by
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using tissue homogenizer followed by sonication at 4 °C
for 5 min. The homogenate was subsequently filtered
using a whatmann filter paper and final volume made up
by methanol. The filtrate was mixed thoroughly with
0.2 ml volume of double distilled water for removal of
non-lipid contaminants. The mixture was kept for
30 min and centrifuged at 5000 rpm for 5 min.; upper
phase was removed, and lower phase was collected with
mammary gland lipids. Methyl esters for the lipid sam-
ples were prepared by stirring 0.5 gm of samples with
hexane (2 ml). Methanolic KOH (2 N) (0.2 ml) was
added to the above mixture and vortexed for 15 min.
The phases were allowed to settle down, and the upper
layer containing the FAME was collected [29].
The FAME samples were filtered using 0.2 μm syr-
inge filters and subjected to the gas chromatographic
analysis (Perkin Elmer GC- clarus 480; Column : Elite-5
Length-30 mt, Internal diameter- 0.25 mm) using
Flame ionization detector(250 °C; carrier gas: nitrogen
(10 psi); volume of injection 1 μl; Oven temperature:
150 (1 min), ramp 1–5 °C/min to 230 °C (5 min), ramp
2–150 °C /min to 245 for 12 min; internal standard :
cetyl alchohol [30].
Western blotting
Protein samples were prepared from the mammary
gland tissue through acetone precipitation and quanti-
fied by using the Bradford reagent [31]. SDS-PAGE ana-
lysis was performed following the principles of laemmli
with slight modifications [32]. Briefly, protein samples
were mixed with sample buffer (125 mM Tris–HCl,
pH6.8, 20 % glycerol, 4 % SDS, 0.05 % bromophenol
blue, 10 % 2-mecaptoethanol). A 30 μg of protein sample
was allowed to resolve through 12 % polyacrylamide gel
using SDS-PAGE (GX-SCZ2+, Genetix Biotech Asia Pvt.
Ltd, New Delhi). The proteins as resolved through SDS-
PAGE were transferred to a PVDF membrane (IPVH
00010 Millipore, Bedford, MA USA) using semidry
transfer (GX-ZY3, Genetix Biotech Asia Pvt. Ltd, New
Delhi). Subsequently, membrane was blocked with 3 %
BSA and 3 % not fat milk in TBST for 2 h and incubated
overnight with primary antibody against Pgp 9.5(MA1-
83428) (1:2000 dilution), NF-kBP65 (MA5-1616) (1:2000)
and β-actin MA5-15739-HRP(1:3000 dilution) (Pierce,
Thermo Scientific, USA). The membrane was washed
with TBST thrice and incubated with HRP conjugated rat
anti-mouse secondary antibody (31430, 1:5000 dilutions)
(Pierce Thermo Scientific, USA) at room temperature
for 2 h. The signals were detected using an enhanced
chemiluminescence substrate (Wester Bright ECL HRP
substrate, Advansta, Melanopark, California, US). The
Quantification of protein was done through densiometric
digital analysis of protein bands using Image J software
[32, 33].
Results
The results revealed significant inflation in the AB/TEB’s
score with MNU treatment which was dose-dependently
curtailed down with the β-sitosterol treatment. A similar
pattern of negating effects was evident for the β-
sitosterol, when scrutinized for the differentiation score
in the whole mount of the mammary gland (Table 1;
Fig. 1). The TBARs levels were significantly upraised
with MNU administration, and β-sitosterol was evident
for a significant curtailment of the same. The tissue cata-
lase, SOD, and GSH levels were diminished after the
MNU and high dose of β-sitosterol helped to restore the
tissue catalase level without affecting the SOD levels
(Table 2). It would be appropriate to remark that low
dose of β-sitosterol failed to regulate the oxidative stress
markers favorably. In fact low dose of β-sitosterol
embarked a diminishing effect on the oxidative stress
markers. NO levels were replenished dose dependent
way in β-sitosterol treatment but less than sham control,
but LOX activity was up-regulated with the higher dose
of β-sitosterol (Fig. 2). When contemplated on the accounts
of the fatty acid profile of the mammary gland tissues, a sig-
nificant decrease in the saturated and unsaturated fatty acid
was evident with the MNU treatment (Table 3, Fig. 3). The
MNU treatment was evident with the increased Pgp levels
which were further up-regulated after the β-sitosterol treat-
ment (Fig. 4). Treatment with MNU also afforded up-
Table 1 Effect of MNU and β-sitosterol on differentiation of mammary gland
Groups AB1 AB2 AB1 + AB2 LOBULES DF SCORE- 1
(AB1 + AB2 + LOBULES)
DF SCORE 2
(LOBULES/AB1 + AB2)
CONTROL (3 ml/kg) 685.75 ± 223.36 367.75 ± 79.88 1053.5 ± 302.45 1805.75 ± 460.39 2859.25 ± 756.67 1.76 ± 0.09
MNU (47 mg/kg) 786.5 ± 20.56 432.5 ± 36.60 1219 ± 57.17 2606 ± 243.72 3825 ± 300.89 2.13 ± 0.09
β-SITOSTEROL +MNU
(10 mg/kg + 47 mg/kg)
532 ± 178.53 201.5 ± 48.64* 733.5 ± 227.17 1774.5 ± 417.74 2508 ± 644.92 2.48 ± 0.19
β-SITOSTEROL +MNU
(20 mg/kg + 47 mg/kg)
380.5 ± 111.83 143 ± 2.00** 523.5 ± 113.83 1390.5 ± 142.92 1914 ± 256.76 2.72 ± 0.31
(Values are Mean ± SEM), each group contains eight animals. Comparisons were made on the basis of the one-way Anova followed by Bonferroni test. All groups
were compared to the toxic control group (*p < 0.05, **p < 0.01)
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regulated expression of NF-kB, which was curtailed down
after the β-sitosterol treatment (Fig. 4).
Discussion
The present study perceived critical protection by β-
sitosterol to combat the deleterious effects of MNU on
the mammary gland. The whole mount preparations are
frequently used as a convenient method for the examin-
ation of small proliferative lesions as represented by an
increase in the number of terminal end buds (TEBs)
[34]. The AB/TEB is the morphologic structure reported
to be the target of carcinogenic outcome in the rat
mammary gland carcinoma and also the structure from
which premalignant pathologies changes in ductal car-
cinoma [35]. We considered it primary to determine
whether the vascularisation and angiogenesis of TEBs
was affected by MNU administration. If angiogenesis
was increased, then a decrease in vascularity of TEB by a
I II
III IV
Fig. 1 Whole mount of mammary gland tissue subjected to carmine staining: Group I: Control, Group II: MNU, Group III: β-sitosterol (10 mg/kg),
Group IV: β-sitosterol (20 mg/kg)
Table 2 Effect of β-sitosterol upon various in-vivo antioxidant markers
Groups TBARs (nM of MDA/μg
of protein)
GSH (mg %) SOD (Units of SOD/mg
of protein)
Catalase (nM of H2O2/min/mg
of protein)
CONTROL (3 ml/kg) 86.08 ± 5.00*** 2.30 ± 0.12 1.92 ± 0 50.63 ± 7.81*
MNU (47 mg/kg) 118.84 ± 4.65 2.00 ± 0.16 1.81 ± 0.02 31.76 ± 2.59
β-SITOSTEROL +MNU
(10 mg/kg + 47 mg/kg)
147.93 ± 6.67** 1.03 ± 0.14** 1.82 ± 0.03 26.90 ± 3.06
β-SITOSTEROL +MNU
(20 mg/kg + 47 mg/kg)
105.51 ± 2.35 1.24 ± 0.21* 1.80 ± 0.03 51.75 ± 3.31*
(Values are Mean ± SEM), each group contains eight animals. Comparisons were made on the basis of the one-way ANOVA followed by Bonferroni test. All groups
were compared to the toxic control group (*p < 0.05, **p < 0.01, ***p < 0.001)
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cancer preventive agent is expected. Therefore, TEBs/AB
is potentially used as an early positive marker of antian-
giogenic cancer preventive activity [36]. The MNU treat-
ment was evident with a rise in AB/TEBs count and
differentiation score, and can be closely linked to in-
creased risk of mammary tumourigenesis. These iden-
tical mammary structures are the sites of malignant
transformation in the rat mammary gland [34] and
the corresponding structures in the human breast are
the terminal ductal lobular units [37]. Studies have
shown that higher number of AB/TEBs correlates
with greater risk of mammary cancer [34]. Treatment
with MNU was evident with an increase in some al-
veolar bud score and differentiation score which was
counteracted by β-sitosterol to the sizable amount in
a dose-dependent manner.
Fig. 2 Effect of MNU and β-sitosterol on inflammatory markers and nitric oxide level: GroupI : Control, Group II: MNU, Group III: β-Sitosterol
(10 mg/kg), Group IV : β-Sitosterol (20 mg/kg)
Table 3 Fatty acid profiling of mammary gland tissue treated with MNU and β-Sitosterol





(20 mg/kg)Name Saturated Unsaturated
1 C4:00 Butanoic acid 0.01 - - -
2 C6:00 Hexanoic acid 0.04 0.02 - -
3 C8:00 Octanoic acid 0.80 0.44 0.36 0.31
4 C10:0 Decanoic acid - 0.05 0.05 0.03
5 C11:0 Undecanoic acid 4.65 2.34 1.64 1.62
6 C12:0 Dodecanoic acid 18.08 10.47 7.94 6.92
7 C13:0 Tridecanoic acid 0.07 0.05 0.04 0.03
8 C14:0 Tetradecanoic acid 6.52 3.36 2.30 3.90
9 C14:1 Myristoleic acid(ω-3) 27.68 16.14 13.35 10.83
10 C15:0 Pentadecanoic acid 1.98 1.06 0.96 0.18
11 C17:1 Heptadecanoic acid 0.13 0.10 0.14 0.06
12 C18:0 Octadecanoic acid 0.01 0.00 0.07 0.08
13 C18:1 Oleic acid(ω-9) 0.00 0.03 0.01 0.03
14 C18:2 Linoleic acid (ω-6) 0.02 0.03 0.02 0.02
Total fatty acid 59.94 34.09 26.88 24.64
Saturated fatty acid 32.24 17.89 13.5 13.76
Unsaturated fatty acid 27.7 16.2 13.38 10.88




Fig. 3 FAME of the mammary gland tissue subjected to MNU and β-sitosterol: Group I: Control, Group II: MNU, Group III: β-sitosterol (10 mg/kg),
Group IV: β-sitosterol (20 mg/kg)
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Chronic inflammation and release of NO results in
DNA damage and nitrosylation of proteins which has
been implicated in carcinogenesis. The COX and LOX
inhibitors have been deliberated to have anticancer activ-
ity since long [38]. Infact, over expression of COX and
LOX in progression and neo-angiogenesis of human
cancer has been supported by large body of scientific lit-
erature [39, 40]. A recent finding also affirmed that the
COX-2 over expression can induce mammary gland car-
cinogenesis by reducing the proapoptotic (BAX and
BCL-XL) and inflating the antiapoptotic proteins (BCL-
2) expression in the mammary gland tissue [41, 42].
Overexpression of LOX has also been reported in variety
of tumors including breast, colorectal and prostate can-
cer [43, 44]. In line with the previous reports upregu-
lated COX levels were perceived after MNU treatment
and β-sitosterol afforded a marked reduction of the
same. However, MNU treatment downregulated LOXs
in the course of tumor development suggesting that
LOX exhibit antitumorigenic rather protumorigenic ef-
fects. Infact decreased LOX activity has been reported in
the prostate cancer, high-grade prostatic intraepithelial
neoplasia and human colon cancer and therefore
represent a research question which needs to be ad-
dressed to its full [45–47].
NF-kB is a group of sequence-specific transcription
factor and is best known as a key regulator of inflamma-
tory responses [48]. Elevated NF-kB DNA binding activ-
ity is detected in both mammary carcinoma cell lines
and primary human breast cancer tissues. In fact, NF-kB
is reported to contribute expansion of breast tumor stem
cells and enhancement of vasculogenesis [49] and,
therefore, has emerged as a viable target for cancer
progression. In the same line, we perceived significant
up-regulation of the levels of NF-kB in MNU treated
animals, which subsided to a significant amount by β-
sitosterol treatment. The efficacy of β-sitosterol to
nudge down NF-kB is in agreement with the previous
findings [49]. Prima faci it appears that β-sitosterol
can impart a noticeable effect against the MNU in-
duced carcinogenesis.
The link between MNU induced carcinogenesis and
oxidative stress regulators is well established [50, 51].
The oxidative stress is defined as an imbalance in the
production of reactive oxygen species (ROS) and re-
active nitrogen species (RNS) leading to impaired
Fig. 4 Western Blot analysis: Group I: Control; Group II: MNU; Group III: β-sitosterol10 mg/kg; Group IV: β-sitosterol 20 mg/kg. The western blot
analysis containing whole tissue lysate from rat mammary gland was probed for P-gp 9.5 antibody; its immunoreactivity was evident as a band of
molecular weight of 27 kDa. In case of control the expression is low in comparison with the toxicant. The low and high dose of β-sitosterol shows
a similar pattern of elevated expression in a dose dependent manner. Results of the β-actin analysis are shown as an internal control
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cellular metabolism and changes in the intra and
extracellular environmental conditions. ROS and RNS
can further lead to DNA damage such as mutations,
deletions, amplifications and rearrangements which
can lead to cancer initiation and progression. The
effects of ROS and RNS are balanced by the exogen-
ous/endogenous antioxidants acting through enzym-
atic or non-enzymatic mechanisms. Treatment with
MNU deliberated significant rise in TBARs with no-
ticeable downturn in the enzymatic defense of SOD/
catalase/GSH. The NO levels were also curtailed
down subsequent to MNU treatment. The drop in
the oxidative defense and up-regulation of the lipid
peroxidation products is a clear testimony of oxidative
stress and is in line with the previous reports about
MNU induced carcinogenesis [52, 53]. Treatment with
β-sitosterol demarcated significant restoration of the
oxidative stress markers at a higher dose. Interest-
ingly, β-sitosterol at lower dose deteriorated the
markers of oxidative stress, in particular, TBARs,
GSH and enzymatic levels of catalase. Authors would
not like to mention that the results scrutinized with
the low dose of β-sitosterol are neither in line with
the previous reports, nor in consonance with the
findings elaborated by us in the preceding section of
the manuscript. All in all, one can conclude that β-
sitosterol can impart a demarcating biochemical effect
on the MNU induced carcinogenesis through modify-
ing the inflammatory signaling and regulating the oxi-
dative stress markers at higher dose.
Pgp-9.5 (ubiquitin COOH-terminal esterase L1 or
UCHL-1) is an ubiquitin COOH terminal hydrolase that
is widely expressed in different type of cancer cells [18].
Recent study demonstrated that Pgp-9.5 is highly over-
expressed at many non-neuronal tumors, including
breast, colorectal and pancreatic tumors [19]. There are
very few studies, carried out in the particular subtype of
ER positive breast cancers and result are also non-
conclusive [54]. PGP-9.5 expression is significantly
associated with higher MVD (intratumoral microvessel
density) in ER negative breast cancer [55]. Their actual
role and underlying mechanism is not properly under-
stood in case of ER or PR receptor positive breast cancer
produced by MNU treatment [54]. In this particular
study the toxic group showed elevated expression in
comparison with control, which ensures overexpression
of Pgp-9.5 in MNU induced toxicant group. Pgp-9.5
overexpression in the primary cancerous tissues is due
to biological transformations, imparting it the status of
oncogenic marker [56–58]. UCHL-1 encodes two oppos-
ite characteristic pattern in the ubiquitin pathway. When
ubiquitin COOH terminus hydrolase to generate another
single ubiquitin, the other end show ligase activity which
lead to multiple ubiquitination. Different animal studied
showed that on application of apoptotic stimuli, UCHL-
1 overexpression does not happen [59]. The previous re-
sults suggest that Pgp-9.5 is more likely to be act as a
tumor suppressor molecule, which is in line with our
experimental outcome [60–62]. The dose dependent
increase in Pgp-9.5 expression was observed after β-
sitosterol treatment.
Fatty acids are important modifiers of the mammary
gland carcinoma risk and are composed of complex mix-
tures including the saturated, monounsaturated and
polyunsaturated fatty acids. Modifying the fatty acid pro-
file has been found to be closely associated with mam-
mary gland cancer risk in rodent models and humans
[63–65]. Plethoras of scientific studies are available
pointing the positive association between saturated/
monounsaturated fatty acid and progression of mam-
mary gland carcinoma, with a negative modulation by
polyunsaturated fatty acid. Similar framework of de-
creased total polyunsaturated fats and increased satu-
rated/monounsaturated fat in the mammary gland was
scrutinized after the MNU treatment. β-sitosterol
afforded to curtail down the upraised saturated/mono-
unsaturated fats profile in the mammary gland tissue
dose-dependently without much affecting the total
PUFA concentration. It would be appropriate to mention
that total fat in a cancerous tissue has been directly cor-
related drug resistance and subsequently Pgp expression.
In fact inhibition of the multidrug resistance, MDR1/P-
gp has been postulated as one of the mechanism
through which polyunsaturated fatty acids exert a syner-
getic effect in the response of tumor cells to anticancer
drugs [66]. In the present study, we contemplated over-
expressed Pgp and diminished unsaturated fatty acid
after the MNU treatment and vice versa results after the
β-sitosterol administration. The up-regulated PUFA
levels after the β-sitosterol treatment also strengthens
the previous observations that β-sitosterol can promote
apoptosis through activating FAS enzyme.
Conclusion
With all above one can conclude that β-sitosterol can
impart significant protection against the MNU in-
duced mammary gland carcinogenesis through modi-
fying the pathological, biochemical and inflammatory
markers, which authors would like to attribute to its
modulatory activity towards Pgp and fatty acid profile
of the mammary gland. Authors would also like to
hypothesize that the same could be attributed to its
potential to activate FAS and thereby promote apop-
tosis. However, because FAS is primarily regulated
through the hypoxia-inducible factor and subsequently
prolyl hydroxylase, it would interest to investigate the
effect of β-sitosterol on the same.
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